Category: Gastroenterology

  • IBD Clinic Notes: A Structured Reading and Review Checklist

    IBD clinic notes can become a long list of treatments and test results without a clear account of the question being addressed. A structured review helps clinicians organise their reading and prepare a coherent summary. The checklist below is an educational framework to adapt to local documentation standards and individual clinical circumstances.

    Begin with the purpose of the review

    State why the patient is being reviewed and what decision or concern needs attention. Keep the patient’s priorities visible alongside the clinical agenda. Separate what the patient reports from findings in earlier records, and identify information that has not yet been confirmed.

    For study purposes, turn the consultation question into a reading question. “What information would help assess this change?” is more focused than “read everything about IBD”.

    Summarise the history without copying the whole record

    Identify the established diagnosis and relevant disease history, previous investigations, procedures and treatment experience. Include dates and sources where they matter. If a diagnosis, classification or historical event is uncertain, label that uncertainty instead of converting it into a firm statement through repeated copying.

    Keep a distinction between the treatment prescribed, what is recorded as being taken, and any reported difficulty using it. Specific prescribing and monitoring decisions require current guidance and the appropriate clinical team.

    Bring current concerns and objective information together

    Organise the available information into a short summary: current symptoms and their course, relevant examination findings, available investigations and outstanding results. Make it clear when a result was obtained and whether it answers the current question.

    The 2025 British Society of Gastroenterology guideline addresses adult IBD care and supports clinical decision-making while recognising the need to tailor decisions to individual circumstances. Use the full guideline for clinical recommendations rather than treating a brief checklist as a management protocol.

    Document the reasoning and the next step

    A useful plan explains which question remains open, what information or action is needed, who is responsible and how follow-up will occur. Record the discussion and the patient’s preferences according to your professional responsibilities and local procedures.

    For an educational case review, use this simple sequence:

    1. Define the current problem in one sentence.
    2. List the evidence available and its dates.
    3. Identify the missing information.
    4. Locate the relevant current guidance.
    5. Explain the decision and how it will be reviewed.

    If the clinical situation requires urgent assessment, a routine documentation or reading exercise must not delay the appropriate care pathway.

    Keep study notes separate from patient records

    Use fictional or appropriately anonymised cases in personal learning notes, following your organisation’s policies. A learning template should not become an informal store of identifiable patient information. Record clinical care in the authorised system.

    Read further

    IBD for Clinicians brings diagnosis, treatment and monitoring topics together with cases and reference material. Review its contents and sample information to see how it fits your learning needs.

    Clinical source: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. This article is a reading and documentation framework, not a patient-specific treatment recommendation.

  • Treat to target in IBD: the idea behind modern monitoring

    For many years, success in inflammatory bowel disease was judged by how the patient felt. If the diarrhoea settled and the pain eased, all was well. We now know that symptoms and inflammation do not always move together. A patient can feel well while inflammation continues to damage the bowel.

    Treat to target is the response to that discovery. It means agreeing measurable goals at the start, checking them at planned times, and reviewing the plan with the IBD team when a goal is not met.

    The targets

    Targets are usually layered by time. In the short term the aim is relief of symptoms. Blood and stool markers of inflammation should then return to normal. In the longer term the aim is healing of the bowel lining, because mucosal healing is linked with fewer flares, fewer admissions and less surgery. Quality of life and the absence of disability sit alongside these goals.

    How the targets are measured

    Faecal calprotectin is the workhorse of monitoring. It is non-invasive, can be repeated, and often rises before symptoms return. C-reactive protein helps in some patients. Endoscopy remains the reference standard for assessing healing, and intestinal ultrasound and MR enterography are increasingly used to assess the small bowel in Crohn’s disease.

    Why the idea matters

    The value of treat to target lies in planning. Each check has a date, each result is compared with the agreed goal, and the patient knows what is being measured and why. It turns follow-up from waiting for the next flare into a structured conversation.

    For exams and for practice

    Treat to target is now part of the language of IBD in guidelines and in specialty exams. Physicians are expected to know what the targets are, how they are measured and how the scores used in IBD relate to them.

    IBD for Clinicians explains the targets, the scores used to measure them and the monitoring tools in line with the 2025 BSG guideline.

  • Acute severe ulcerative colitis: an overview for physicians

    Acute severe ulcerative colitis is one of the true emergencies of gastroenterology. It can affect patients with known colitis or be the first presentation of the disease, and it still carries a real risk of colectomy. Any physician who admits patients on the medical take should be able to recognise it.

    Recognition

    The modified Truelove and Witts criteria are used to define a severe attack. They combine the number of bloody stools a day with signs of systemic upset, such as a fast pulse, fever, anaemia or raised inflammatory markers. The criteria are simple to apply at the bedside and appear frequently in exams.

    Why it is an emergency

    Severe colitis can progress to toxic dilatation of the colon, perforation, bleeding and sepsis. Patients are also at increased risk of venous thromboembolism. Delay in recognising severity, or in involving the right teams, is a recognised cause of harm.

    Things to exclude

    Infection can mimic or complicate a flare. Stool tests, including testing for Clostridioides difficile, are part of the initial assessment, and biopsies help to look for cytomegalovirus in selected patients.

    A joint approach

    Patients with acute severe colitis are cared for by gastroenterologists and colorectal surgeons together from the start, with regular joint review. Patients and families should be involved early in discussions about the possible outcomes, including surgery, so that decisions are not made in a hurry.

    For exams and for practice

    Exam questions usually test recognition of severity, the importance of excluding infection, and the role of planned reassessment. In practice, the same priorities apply: early recognition, early specialist involvement and clear communication.

    IBD for Clinicians covers acute severe colitis alongside the other IBD emergencies, with the scores and decision points explained for clinicians.

  • IBD for Clinicians: what the book covers and who it is for

    Caring for someone with inflammatory bowel disease is no longer only about controlling diarrhoea and pain. The aim of modern treatment is sustained, steroid-free remission, prevention of bowel damage, and protection of nutrition, function and quality of life. Reaching that aim depends on getting many decisions right: the diagnosis, the choice of drug, the timing of escalation, and the monitoring that follows.

    IBD for Clinicians was written to bring those decisions together in one place, updated against the 2025 British Society of Gastroenterology guideline on IBD in adults.

    What is inside

    • Diagnosis and classification, with a defensible strategy for biopsies and imaging.
    • Disease activity scores worked through, including Truelove and Witts, Mayo, the Harvey-Bradshaw Index, CDAI, SES-CD, Rutgeerts and PUCAI.
    • Treatment strategy for ulcerative colitis and Crohn’s disease.
    • Thiopurines and methotrexate, including TPMT and NUDT15 testing and metabolite interpretation.
    • Biologics and small molecules with current UK dosing and NICE and MHRA positions, plus therapeutic drug monitoring.
    • Emergencies, including acute severe colitis.
    • Perianal disease, surgery and pouchitis.
    • Pregnancy, vaccination and infection prevention.
    • Extraintestinal manifestations, nutrition and iron.
    • Treat-to-target monitoring and colorectal cancer surveillance.

    Who it is for

    The book is a working companion for gastroenterology trainees and consultants, IBD specialist nurses, pharmacists and general physicians who see patients with IBD on the ward or in clinic. It is also written with exams in mind: the scores and treatment pathways are the ones candidates are expected to know for specialty examinations.

    It is not a replacement for local protocols or for the full guideline. It is designed to sit beside them, so that the essentials of current UK practice are quick to find when a decision has to be made.

    IBD for Clinicians is available as a Kindle eBook and a paperback on Amazon.